Alternating hemiplegia of childhood: 2026 so far

Reports described different responses from person to person, without controlled evidence of benefit.

In January 2026 to September 2026, treatment evidence did not move into controlled testing, and medication effects were mostly described as variable in routine care. One small series of fever-triggered ATP1A3 episodes reported different medication responses and included an example of flunarizine use, without a consistent pattern across individuals. A Brazilian multicenter ATP1A3 series also described mixed and incomplete medication experience. It included reduced hemiplegic episodes with flunarizine in some people, limited benefit with levodopa (1 of 11), and mixed topiramate responses, including one report of worsening. This means families and clinicians are still often left using individualized trial-and-observation, rather than relying on clearly proven medication effects from these reports.

Research covered in: May 2026, August 2026

Small reports again pointed to illness and fever as major triggers.

In several small clinical reports from the months covered, fever and infections repeatedly showed up as strong triggers for sudden neurologic worsening in ATP1A3-related conditions, including presentations labeled as AHC. A January report described two children with febrile infection-triggered episodes that included reduced reflexes and could resemble Guillain-Barre syndrome (a nerve condition that causes weakness), along with movement symptoms. A May report supported this pattern in a 7-person case series that included several ATP1A3-related labels. It also noted wide differences in severity even within the same family, and that routine tests (MRI/EEG) were often not specific. In these small series, illness-associated episodes could look unexpected and may not be clearly explained by standard testing.

Research covered in: January 2026, May 2026

Larger cohorts connected early course and epilepsy with outcomes.

Cohort data reported in the months covered suggested that the most noticeable worsening in thinking skills and baseline (non-attack) disability clustered in early childhood, with several measures appearing more stable after about age 5 in that cohort. In the same international group, epilepsy (recurrent seizures) was linked with worse disability-related scores. Mortality during follow-up included SUDEP (sudden unexpected death in epilepsy) among those with epilepsy. A September report added a practical tracking tool: the AHC Rating Scale (AHC-RS) showed excellent agreement between different clinician raters and moderate alignment with other movement/disability measures in a European sample. Together, these findings support more structured ways to describe severity, and they highlight signals (especially epilepsy and early disability) that were associated with harder outcomes in these cohorts.

Research covered in: August 2026, September 2026

Studies highlighted overlap and severe presentations that can resemble other diseases.

Evidence from January 2026 to September 2026 added support for the idea that ATP1A3-related disorders often do not fit one classic label, and that the same variant can be linked to different symptom patterns across people. A study of 88 people with ATP1A3 variants found most had a mix of chronic movement symptoms and episodic events, and it introduced a curated video archive to document and compare episode patterns. A September report added a small case series showing that ATP1A3-related disorders (including AHC) can first look like inflammatory encephalopathy (brain inflammation-like illness) even when MRI and spinal fluid tests are normal, with genetic testing later clarifying the diagnosis. In practice, these reports suggest diagnosis may depend heavily on careful pattern recognition over time and genetic testing, especially when routine tests are non-specific or episodes resemble other neurologic illnesses.

Research covered in: March 2026, September 2026

Lab and imaging studies suggested mechanisms that could be tested, without showing clinical effects.

Mechanism-focused studies in the months covered suggested several variant-linked pathways, without showing clinical effects. Patient-derived heart-like cells with the ATP1A3 D801N variant showed calcium overload, shorter electrical signals, and abnormal extra electrical events in lab models. Blocking the calcium transporter NCX1 shifted signals toward typical in experiments, but the real-life relevance was explicitly uncertain. Two worm-model studies inserted multiple AHC-linked variants and found dominant nerve-to-muscle signaling defects and variant-specific sleep/arousal changes, with inconsistent effects from a tested modifier gene. A small human imaging comparison also reported less efficient whole-brain structural connectivity in AHC than controls, with measures correlating with motor severity and cognitive performance. These studies add research models and candidate pathways that may shape what gets measured and tested next, without changing care yet.

Research covered in: April 2026, May 2026, July 2026, August 2026